Roy Alcalay is an assistant professor of neurology at the Taub Institute and the program director of the Movement Disorders Fellowship at the Columbia University Medical Center. He obtained his medical degree from Tel Aviv University, Israel, his neurology training from the Harvard University residency program at Massachusetts General Hospital and Brigham and Women’s Hospital and his movement disorders training at Columbia University. He is a graduate of the Patient Oriented Research and earned Master’s in biostatistics from Columbia University. His research focuses on biomarkers and genetics in Parkinson’s disease and cognitive functioning. He is a Brookdale Leadership in Aging fellow, and his research is supported by the NIH, the Parkinson’s Disease Foundation, the Michael J Fox Foundation and the Smart Foundation.
His clinical practice focuses on Parkinson's disease and other movement disorders, including tremor, dystonia, Tourette syndrome, myoclonus, ataxia and chorea.
Please contact the doctor's office to verify that your insurance is accepted.
Aetna [EPO, HMO, Medicare, NY Signature, POS, PPO, Signature Administrators, Student Health]
Affinity [Access (Exchange), Essential Plan, Medicaid, Medicare]
Cigna [EPO, Great West, HMO, POS, PPO]
Emblem/HIP [ConnectiCare, EPO, HMO, Medicaid, Medicare, POS, PPO, Select Care (Exchange), Vytra]
Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
Fidelis Care [Child/Family Health Plus, Medicaid, Medicare]
Health First [Child/Family Health Plus, Medicaid, Medicare]
Health Plus - Amerigroup [Medicaid]
Oxford Health Plans [Freedom, Liberty, Medicare]
UnitedHealthcare [Columbia University Employee Plan, HMO, Medicaid (Community Plan), Medicare, POS, PPO]
VNSNY CHOICE [Select Health]
Tel-Aviv University School of Medicine
Residency: Massachusetts General Hospital
37. Alcalay RN, Giladi E, Pick CG, Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 2004 May 6;361(1-3):128-3.